Abstract
It has now been 30 years since the first epidemiologic report linked menopausal estrogen therapy—the exogenous estrogens that, along with progestins, came to be known as “hormone replacement therapy”—with an increased risk of breast cancer ([1][1]). Today, the body of evidence on this
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
